MPI Research constantly strives to grow and adapt to meet ever-changing sponsor needs. This effort was prominently illustrated in 2003 by several expansion and renovation projects at our three facilities. Some of the most significant examples of construction projects at the MPI Research Mattawan site included: 37,000 square feet of additional animal housing space, a new state-of-the-art surgical suite, and a complete renovation and expansion of the Test Material Control and Pharmacy area, which was completed in December. Additionally, 15,000 square feet of new research laboratory space was created with the new divisions: MPI Analytical, adding analytical/bioanalytical services, and MPI CardIon Laboratories, performing in vitro electrophysiology evaluations for cardiac safety. Planning is underway for a new administrative building at the Mattawan facility in 2004, as well as numerous other projects being considered based on our sponsor’s request for new services.

Bill Harrison, President and Chief Operating Officer, for MPI Research commented, “We are extremely proud of the trust our sponsors have placed in MPI Research over the years. This trust has manifested itself in many ways, including our high rate of repeat business and the numerous requests we receive from sponsors to add animal capacity and new services. We have answered these requests over the last year by adding significantly to our animal housing capability, forming two new divisions, and purchasing another. Analytical and bioanalytical services were a critical addition to our product offerings. In vitro electrophysiology cardiac evaluations will soon be a required test to meet the pending ICH S7B guidance and we are prepared to be an industry leader in this area, just as we are now with in vivo safety pharmacology services. Our purchase of FAST Systems, which has been a leader in the area of Flow Cytometry for over 16 years, positions MPI Research as a preeminent CRO in immunotoxicological evaluations. All of these additions are integral components of our efforts to become the best non-clinical CRO in the industry.”

MPI Research exists to provide comprehensive non-clinical research that meets the requirements of pharmaceutical, medical device, animal health and chemical companies as well as governmental agencies as we partner together to bring safer, healthier products to the world. MPI Research employees specialize in a wide variety of scientific disciplines including toxicology, pharmacology, metabolism, pathology, clinical pathology, reproductive and developmental biology, veterinary science, neuroscience, experimental therapeutics, immunotoxicology, analytical chemistry, computer science, regulatory science, and statistics.

Home | News